A Pivotal Study of LIPUS-Brain in Patients with Early Alzheimer's Disease
- Conditions
- D000544Early Alzheimer's Disease
- Registration Number
- JPRN-jRCT2032230125
- Lead Sponsor
- Shimokawa Hiroaki
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 220
1) Provide written informed consent to participate in the clinical trial from the patient and their legal representative.
2) Mild AD or MCI due to AD patient aged greater than or equal to (>=) 50 and less than (<) 90 years, at the time of informed consent.
3) Patients with the same partner/informant who meet all of the following conditions during the study period.
a) Living with or in contact with the patient
b) It is possible to observe the patient's activities of daily living and physical condition.
c) Being able to be present at all times during the efficacy evaluation specified in this clinical trial
d) Person judged by an investigator to be able to manage administration of concomitant medications
4) Patients who met the diagnostic criteria of Mild AD or MCI due to AD according to the NIA/AA 2018 diagnostic criteria at the time of informed consent and were diagnosed as positive by the amyloid PET imaging evaluation committee.
5) Have a CDR global score of 0.5 (MCI due to AD) to 1.0 (Mild AD) at screening.
6) Patients with her MMSE-J score >=20 at screening.
7) No organic diseases such as symptomatic cerebral hemorrhage, symptomatic cerebral infarction, acute cerebral infarction, brain tumor, etc. within 48 weeks before obtaining informed consent or in head MRI images at screening, and in head MRA images, Patients evaluated by the imaging evaluation committee as not having severe stenosis/occlusion from the internal carotid artery to the middle cerebral artery.
8)Patients who are receiving existing drug therapy for Mild AD or MCI due to AD and are not scheduled to change their medication within the past 4 weeks from obtaining consent and after obtaining consent.
1) Patients judged by the investigator that it is difficult to continue the study treatment for 20 minutes.
2) Patients judged by the investigator to be difficult to perform an MRI examination.
3)Patients with impaired consciousness with a GCS score of 12 or less at the time of enrollment.
4) Patients who have had symptomatic cerebral infarction or cerebral hemorrhage within 12 weeks prior to enrollment.
5) Patients with a modified Hachinski Ischemic Scale score of 5 or more at enrollment.
6) Patients with Lewy body dementia and frontotemporal dementia.
7) Patients judged by the investigator to be difficult to participate in the clinical trial due to severe mental illness.
8) Poorly controlled serious systemic disease (heart failure, liver failure, renal failure, vitamin B12 deficiency, hypothyroidism, etc.) that makes it difficult for the investigator to participate in the study judged patient.
9)Patients with uncontrolled diabetic retinopathy (with active fundus hemorrhage).
10)Patients who have malignant tumor as a complication or who have been treated for malignant tumor within 5 years from the time of enrollment (excluding cured resected carcinoma in situ).
11) Patients who are or have a history of drug addiction or alcohol addiction.
12) Patients with or with a history of epilepsy.
13)Patients with implants such as coils, electrodes and stents in the skull.
14) Patients within 5 years after brain surgery (including endovascular treatment).
15) Patients who are pregnant or wish to become pregnant.
16) Patients participating in other clinical studies (excluding non-interventional observational studies) or clinical trials.
17) Patients who are otherwise judged to be ineligible by the investigator.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Changes in ADAS-J-cog-14 scores from baseline to 72 weeks
- Secondary Outcome Measures
Name Time Method '- Changes in ADAS-J-cog-14 scores from baseline to 24 and 48 weeks.<br>- Changes in CDR-SB from baseline to 48 and 72 weeks.<br>- Changes in MMSE-J, FAQ, NPIQ-J, J-ZBI, WMS-R, EQ-5D-5L and ABC from baseline to 24, 48 and 72 weeks.<br>- Prevalence of responders at 24, 48, and 72 weeks defined as those with no deterioration or even improvement in ADAS-J-cog-14 scores.<br>- Transition rate from MCI due to AD to AD at 72 weeks.<br>- The safety endpoints include adverse symptoms until 72 weeks and any abnormal MRI findings at 72 weeks.<br>- Termination due to aggravation of dementia symptoms.